Bodal Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BODALCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.9 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bodal Chemicals reported consolidated revenue of Rs. 20,122.42 million for FY 2025-26, up 15% from Rs. 17,484.29 million in the previous year. Profit after tax nearly doubled to Rs. 320.60 million from Rs. 145.04 million, representing strong PAT growth. However, EBITDA margin compressed significantly from 6.7% to 3.5% due to higher finance costs of Rs. 178.28 million. The Board approved the sale of Unit-I at Vatva, Ahmedabad (book value Rs. 62.96 million), which was already closed since May 2024. Earlier, the company had sold Unit-II and Unit-III during the year, generating Rs. 263.50 million profit included in other income. The auditors issued an unmodified opinion with an emphasis of matter on Rs. 269.80 million SGST incentive income recognized under the Punjab Industrial Incentive Scheme.
Strong PAT growth is positive for shareholders, but margin compression due to high finance costs may concern investors. The ongoing disposal of non-core inoperative units reflects asset rationalisation, with the total assets held for sale now at Rs. 254.95 million.